- Home
- GNLX vs SOPH Comparison
GNLX vs SOPH Comparison
Compare GNLX & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | SOPH |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 330.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNLX | SOPH |
|---|---|---|
| Price | $4.32 | $4.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $19.75 | $7.00 |
| AVG Volume (30 Days) | ★ 195.5K | 101.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $73,297,000.00 |
| Revenue This Year | N/A | $18.32 |
| Revenue Next Year | N/A | $15.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.66 |
| 52 Week Low | $1.99 | $2.58 |
| 52 Week High | $8.54 | $5.30 |
Technical Indicators
Market Signals| Indicator | GNLX | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 52.09 |
| Support Level | $4.37 | $4.54 |
| Resistance Level | $4.75 | $4.84 |
| Average True Range (ATR) | 0.42 | 0.30 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 8.99 | 39.25 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.